<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05040737</url>
  </required_header>
  <id_info>
    <org_study_id>Dial-COVID</org_study_id>
    <nct_id>NCT05040737</nct_id>
  </id_info>
  <brief_title>PMMA vs Polysulfone in SARS-CoV-2 Infection Hemodialysis Patients</brief_title>
  <acronym>Dial-COVID</acronym>
  <official_title>Comparison of Two Types of Dialyzers (PMMA vs Polysulfone) on Cytokine Extraction in Hemodialysis Patients and COVID Infection. A Multicenter Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación para la Investigación del Hospital Clínico de Valencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación para la Investigación del Hospital Clínico de Valencia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Controlled, prospective, open-label trial with a total duration of 2 weeks to assess the&#xD;
      clearance of inflammatory interleukins by different membranes in haemodialysis patients with&#xD;
      COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Controlled, prospective, open-label trial with a total duration of 2 weeks to assess the&#xD;
      clearance of inflammatory interleukins by different membranes in haemodialysis patients with&#xD;
      COVID-19.&#xD;
&#xD;
      Patients will be dialysed according to the usual dialysis schedule of three weekly sessions.&#xD;
      The study has a duration of 8 days in order to include 4 haemodialysis sessions. The first&#xD;
      and third haemodialysis sessions will be dialysed with PS membrane and the second and fourth&#xD;
      sessions with PMMA membrane, both dialysers with a surface area of 1.8 m2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 17, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">February 8, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Inflammatory interleukins reduction with two different dialysis membranes (PMMA and PS).</measure>
    <time_frame>Day 8</time_frame>
    <description>To compare the percentage reduction of inflammatory interleukins measured at the beginning and end of haemodialysis in the same patient with COVID 19 infection dialysed with two different dialysis membranes (PMMA and PS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Inflammatory interleukins reduction</measure>
    <time_frame>Days 5 and 8</time_frame>
    <description>Inflammatory interleukins reduction maintenance with each membrane after a second dialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory interleukins reduction (30 minutes)</measure>
    <time_frame>Days 1,3,5,8</time_frame>
    <description>Inflammatory interleukins percentage reduction 30 min after each session,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Populational characteristics</measure>
    <time_frame>Day 8</time_frame>
    <description>To describe the characteristics of haemodialysis population affected by COVID -19</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Study Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be dialysed according to the usual dialysis schedule of three weekly sessions. The study has a duration of 8 days in order to include 4 haemodialysis sessions. The first and third haemodialysis sessions will be dialysed with PS membrane and the second and fourth sessions with PMMA membrane, both dialysers with a surface area of 1.8 m2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PS membrane versus PMMA membrane,</intervention_name>
    <description>Patients will be dialysed according to the usual dialysis schedule of three weekly sessions. The study has a duration of 8 days in order to include 4 haemodialysis sessions. The first and third haemodialysis sessions will be dialysed with PS membrane and the second and fourth sessions with PMMA membrane, both dialysers with a surface area of 1.8 m2.</description>
    <arm_group_label>Study Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years .&#xD;
&#xD;
          -  Patient on chronic haemodialysis admitted to the hospital with a diagnosis of&#xD;
             infection by COVID-19.&#xD;
&#xD;
          -  Signature of informed consent or legal representative.&#xD;
&#xD;
          -  Estimated duration of admission greater than 8 days (4 haemodialysis sessions).&#xD;
&#xD;
          -  Patient with haemodynamic stability, understood as systolic blood pressure ≥ 100 mmHg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to sign the consent form.&#xD;
&#xD;
          -  Patients who for clinical reasons are unable to follow a regular dialysis schedule of&#xD;
             three sessions per week.&#xD;
&#xD;
          -  Allergy (documented or suspected) to either of the two membranes involved in the&#xD;
             study.&#xD;
&#xD;
          -  Patient with haemodynamic instability (Mean arterial pressure &lt; 100 mmHg).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <state>Valencian Community</state>
        <zip>4610</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación para la Investigación del Hospital Clínico de Valencia</investigator_affiliation>
    <investigator_full_name>Mª Jesús Puchades</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Haemodialysis</keyword>
  <keyword>SARS-CoV-2 Infection</keyword>
  <keyword>cytokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

